- Home
- NVA vs ACHL Comparison
NVA vs ACHL Comparison
Compare NVA & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVA
- ACHL
- Stock Information
- Founded
- NVA 1987
- ACHL 2016
- Country
- NVA Australia
- ACHL United Kingdom
- Employees
- NVA N/A
- ACHL N/A
- Industry
- NVA
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVA
- ACHL Health Care
- Exchange
- NVA NYSE
- ACHL Nasdaq
- Market Cap
- NVA 53.1M
- ACHL 56.3M
- IPO Year
- NVA N/A
- ACHL 2021
- Fundamental
- Price
- NVA $11.75
- ACHL $1.39
- Analyst Decision
- NVA
- ACHL Buy
- Analyst Count
- NVA 0
- ACHL 2
- Target Price
- NVA N/A
- ACHL $4.00
- AVG Volume (30 Days)
- NVA 23.3K
- ACHL 2.2M
- Earning Date
- NVA 01-01-0001
- ACHL 05-07-2025
- Dividend Yield
- NVA N/A
- ACHL N/A
- EPS Growth
- NVA N/A
- ACHL N/A
- EPS
- NVA N/A
- ACHL N/A
- Revenue
- NVA N/A
- ACHL N/A
- Revenue This Year
- NVA N/A
- ACHL N/A
- Revenue Next Year
- NVA N/A
- ACHL N/A
- P/E Ratio
- NVA N/A
- ACHL N/A
- Revenue Growth
- NVA N/A
- ACHL N/A
- 52 Week Low
- NVA $0.21
- ACHL $0.63
- 52 Week High
- NVA $19.00
- ACHL $1.41
- Technical
- Relative Strength Index (RSI)
- NVA N/A
- ACHL 68.22
- Support Level
- NVA N/A
- ACHL $1.10
- Resistance Level
- NVA N/A
- ACHL $1.41
- Average True Range (ATR)
- NVA 0.00
- ACHL 0.02
- MACD
- NVA 0.00
- ACHL -0.01
- Stochastic Oscillator
- NVA 0.00
- ACHL 100.00
About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD
Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.